Table 3 Univariable and multivariable analyses examining OS and PFS in association with body composition measures (n = 172)

Age (≥60 years)

1.23

0.63–2.41

0.550

Gender male

0.46

0.22–0.97

0.042

2.39

0.59–9.63

0.222

 Underweight

2.13

0.96–4.75

0.063

1.00

0.21–4.84

0.998

 Obesity

0.92

0.40–2.12

0.839

0.79

0.18–3.48

0.750

HBV

0.81

0.34–1.92

0.631

Alcohol consumption (yes vs no)

0.19

0.03–1.40

0.103

Smoking status (yes vs no)

1.06

0.54–2.07

0.872

BCLC stage (C)

0.94

0.45–1.98

0.878

 1

1.41

0.74–2.69

0.294

0.59

0.20–1.76

0.344

 2

1.17

0.27–5.03

0.834

0.00

0.00

0.987

 3

2.40

0.56–10.34

0.241

0.62

0.08–4.88

0.647

 B

2.19

1.09–4.39

0.028

1.68

0.55–5.15

0.367

 C

7.69

1.02–57.9

0.048

12.43

0.91–170.39

0.059

 Hypertension (yes vs no)

1.10

0.52–2.31

0.801

 Diabetes (yes vs no)

0.97

0.40–2.32

0.941

 Liver Cirrhosis (yes vs no)

0.78

0.42–1.44

0.421

Previous treatment (yes vs no)

0.79

0.33–1.89

0.598

Baseline metastasis (yes vs no)

1.23

0.57–2.65

0.609

0.59

0.21–1.67

0.323

CRP (≥10 mg/L)

2.80

1.12–7.02

0.028

0.53

0.16–1.72

0.289

PCT (≥1 ng/mL)

0.04

0.00–142.19

0.448

NLR (≥2.57) 3

2.01

1.08–3.56

0.028

4.63

1.41–15.19

0.012

 Sarcopenia

4.90

2.52–9.51

< 0.001

5.39

1.74–16.74

0.004

 SMD (low vs high)

1.64

0.89–3.03

0.116

1.06

0.33–3.39

0.920

 VATI (high vs low)

0.30

0.15–0.59

0.001

0.04

0.00–0.46

0.009

 SATI (high vs low)

0.31

0.17–0.58

< 0.001

3.44

0.32–37.31

0.310

 TATI (high vs low)

0.31

0.17–0.57

< 0.001

1.32

0.14–12.60

0.808

 VSR (high vs low)

0.73

0.29–1.86

0.509

Age (≥60 years)

0.94

0.64–1.38

0.748

Gender male

0.79

0.49–1.25

0.307

0.70

0.33–1.47

0.341

 Underweight

1.37

0.83–2.28

0.220

0.93

0.37–2.38

0.882

 Obesity

1.06

0.71–1.59

0.766

0.59

0.28–1.24

0.162

HBV

1.33

0.80–2.22

0.267

Alcohol consumption (yes vs no)

0.72

0.41–1.25

0.238

Smoking status (yes vs no)

1.14

0.81–1.62

0.456

BCLC stage (C)

1.26

0.84–1.88

0.265

 1

1.24

0.89–1.75

0.205

1.25

0.76–2.05

0.387

 2

1.93

0.96–3.88

0.064

1.36

0.34–5.38

0.665

 3

0.75

0.18–3.06

0.690

1.70

0.34–8.58

0.519

 B

1.12

0.73–1.71

0.612

1.55

0.86–2.76

0.143

 C

4.44

1.08–18.30

0.039

2.91

0.59–14.32

0.190

 Hypertension (yes vs no)

0.99

0.66–1.49

0.953

 Diabetes (yes vs no)

0.98

0.61–1.59

0.941

 Liver Cirrhosis (yes vs no)

1.08

0.78–1.50

0.652

Previous treatment (yes vs no)

1.44

0.83–2.49

0.195

Baseline metastasis (yes vs no)

1.56

1.05–2.32

0.027

1.41

0.81–2.43

0.221

CRP (≥10 mg/L)

0.94

0.61–1.43

0.768

1.03

0.61–1.75

0.991

PCT (≥1 ng/mL)

0.80

0.36–1.77

0.588

NLR (≥2.57)

1.07

0.77–1.49

0.676

1.21

0.73–1.99

0.460

Sarcopenia

1.62

1.18–2.28

0.005

1.48

0.82–2.67

0.195

SMD (low vs high)

0.83

0.60–1.16

0.269

0.56

0.32–0.99

0.044

VATI (high vs low)

0.87

0.53–1.43

0.590

1.07

0.37–3.11

0.895

SATI (high vs low)

0.80

0.54–1.18

0.259

1.28

0.37–4.47

0.695

TATI (high vs low)

0.90

0.61–1.33

0.590

0.67

0.21–2.12

0.491

VSR (high vs low)

0.98

0.63–1.52

0.937